Clinical trials: Carbapenem-Resistant Enterobacteriaceae Colonization
Enterobacteriaceae Infections, Multi-antibiotic Resistance
FMT to Eradicate Intestinal Colonization by Carbapenem-resistant Enterobacteriaceae
Antibiotic resistance (AR) is a critical public health threat and one of the greatest challenges of the 21st century. In an estimate of 2019, nearly 700.000 infections and 33.000 attributable deaths from multi-drug-resistant…
- Trial name
- FMT_CRE (NCT05791396)
- Testing
- Donor - FMT
- Where
- Italy
- Volunteers
- 36 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Intestinal Colonization With Multidrug-resistant Bacteria
Eradication of Antibiotic-resistant Bacteria Through Antibiotics and Fecal Bacteriotherapy
This investigator initiated,international, multicenter open-label, randomized controlled trial aims to assess whether a 5 day course of oral nonabsorbable antibiotics (colistin sulfate 2 million IU per os 4x/day and neomycin…
- Trial name
- R-GNOSIS WP3 (NCT02472600)
- Testing
- Colistin, Neomycin, Fecal microbiota transplantation (FMT)
- Where
- 4 sites in France, Israel and 2 more
- Volunteers
- 39 people
- Sponsor
- Stephen Harbarth
Intestinal Multi-drug Resistant Organism Colonization
Further MT for Antibiotic-Resistant Bacterial Colonization
The purpose of this study is to better understand the effectiveness and safety of microbiome therapies (MT) as a treatment for patients with Multidrug Resistant Organism (MDRO) colonization after an infection.
- Trial name
- FAIR (NCT05835206)
- Testing
- Microbiome Therapeutic
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Emory University
Antimicrobial Resistance (AMR), ESBL
One Health Determinants of Rectal Colonization by ESBL-Producing Enterobacterales in the Community
This multicenter cross-sectional observational study aims to determine the prevalence of rectal colonization by extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales among community-dwelling adults in Argentina and…
- Conditions
- Antimicrobial Resistance (AMR), ESBL, Gut Microbiota Dysbiosis, Environmental Exposure
- Trial name
- NCT07818109
- Where
- Argentina
- Volunteers
- 432 people, healthy volunteers welcome
- Sponsor
- Hospital Italiano de Buenos Aires